Phase Space Research

Neurocrine Biosciences

NBIX · Investment summary · as of 12 August 2026

Priced below what the business already delivers

Portfolio decision
Held in the growth book
Position size
6.4%
Price · 12 August 2026
$156.49
12-month target
$199.40 +27%
Expected return
+18.9%
Next decision point
27 October 2026Results expected (estimated)

Business type: Compounder · mature and structurally stable

Size is the strategy's, set against its own position and exposure limits.

Investment view

At $156.49, NBIX requires a 4% five-year revenue growth rate to justify its enterprise value — less than the business already delivers, at 34%.

Estimates have moved fY2026 revenue consensus $3,792.2m -> $3,901.5m (up), FY2026 EPS $9.96 -> $10.17 (up); FY2027 revenue $4,494.3m -> $4,568.4m (up), FY2027 EPS $12.66 -> $12.17 (down — the raised spend guide flows into FY2027 EPS). HOUSE TARGET $199.44 IS below STREET'S $213.13 AND THE ENTIRE GAP IS THE MULTIPLE: Street's average implies 4.83x EV/NTM-sales (their own revenue, same forward net cash) = the median of NBIX's own forward history; house uses 4.50x (~38th pctile) for the spend-guide/IRA de-rating.

The strongest argument against this view: the Zydus Paragraph IV challenge to INGREZZA SPRINKLE breaks the settled 1 March 2038 generic wall years early on a franchise that is 80.5% of TTM revenue ($2,717.5m of $3,373.9m; $716.5m of $959.0m in Q2 2026 = 74.7%).

Underwriting bridge

QuestionEvidence-based conclusion
What drives the business?FY2021-FY2025 GAAP operating margin 9.0/16.7/13.3/24.2/21.6%; TTM to 30 June 2026 23.56%. TTM operating cash flow $898.1m (10-Q, now filed). Zero drawn debt at 30 June 2026 with $1.0bn undrawn secured revolver.
What do we forecast?Revenue growth of 34% demonstrated; a terminal operating margin of 30%; an exit multiple of 14.7x.
What does Street forecast?FY2026 revenue consensus $3,792.2m -> $3,901.5m (up), FY2026 EPS $9.96 -> $10.17 (up); FY2027 revenue $4,494.3m -> $4,568.4m (up), FY2027 EPS $12.66 -> $12.17 (down — the raised spend guide flows into FY2027 EPS).
Where do we differ?HOUSE TARGET $199.44 IS below STREET'S $213.13 AND THE ENTIRE GAP IS THE MULTIPLE: Street's average implies 4.83x EV/NTM-sales (their own revenue, same forward net cash) = the median of NBIX's own forward history; house uses 4.50x (~38th pctile) for the spend-guide/IRA de-rating. On revenue growth, the difference between what the price requires and what the business has demonstrated is +30.9 percentage points.
What is it worth?Twelve-month target $199.40, +27% from the struck price. Scenario-weighted expected return net of costs +18.9%.
Why now?Date not announced — no dated event that would resolve the disagreement is on file

What must go right

  1. By Q3 2026 (~late October 2026) and Q4 2026 (~February 2027)INGREZZA quarterly net product sales at or above $700m in either Q3 2026 or Q4 2026Where it stands: Not determined — no current reading of this metric is on file
  2. By Q3 2026 (~late October 2026)CRENESSITY quarterly net product sales at or above $190m in Q3 2026 — no sequential growth from Q2 2026's $183.5mWhere it stands: Not determined — no current reading of this metric is on file
  3. By Q3 2026 (~late October 2026)VYKAT XR net product sales at or above $95m in Q3 2026, the first full quarter under NBIX ownershipWhere it stands: Not determined — no current reading of this metric is on file

Catalysts and falsifiers

Date or windowEventThesis confirmed ifThesis weakened or refuted if
27 October 2026Next results (date estimated, not issuer-confirmed)Revenue and margin in line with, or above, the house pathA miss that moves the full-year path below the guided floor
Q3 2026 (~late October 2026) and Q4 2026 (~February 2027)INGREZZA quarterly net product sales below $700m in either Q3 2026 or…INGREZZA quarterly net product sales at or above $700m in either Q3 2026 or Q4 2026INGREZZA quarterly net product sales below $700m in either Q3 2026 or Q4 2026
Q3 2026 (~late October 2026)CRENESSITY quarterly net product sales below $190m in Q3 2026 — no…CRENESSITY quarterly net product sales at or above $190m in Q3 2026CRENESSITY quarterly net product sales below $190m in Q3 2026
Q3 2026 (~late October 2026)VYKAT XR net product sales below $95m in Q3 2026, the first full…VYKAT XR net product sales at or above $95m in Q3 2026, the first full quarter under NBIX ownershipVYKAT XR net product sales below $95m in Q3 2026, the first full quarter under NBIX ownership

Dates marked as estimated are drawn from the company’s own reporting cadence, not from an announcement.

Risk and sell discipline

Impairment case

The Zydus Paragraph IV challenge to INGREZZA SPRINKLE breaks the settled 1 March 2038 generic wall years early on a franchise that is 80.5% of TTM revenue ($2,717.5m of $3,373.9m; $716.5m of $959.0m in Q2 2026 = 74.7%). If no stay attached, approval could come sooner. The New Jersey action was dismissed in favor of the Delaware proceeding. An adverse claim-construction or invalidity outcome on the shared valbenazine patent estate, a settlement dated materially before 2038, or an at-risk launch after stay expiry re-prices INGREZZA's terminal value permanently. There is no $2.6bn cash cushion any more: net cash is $481.7m post-Soleno.

Estimated probability 18%, against the 54% level at which the position would be resized. It sits within that level.

Fundamental invalidation

Falsifiable and fundamental — not one of them is a price condition.

Price-based risk trigger

A daily close below $137.71 triggers an immediate review of the thesis and pauses additional buying. It is not an automatic sell unless a separate fundamental invalidation condition has been breached.

Upside sell discipline

On approach to the $199.40 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.

Investment criteria

CriteriaStatusInvestment meaning
QualityMetIs the business worth owning under its declared economic type?
ValuationMetIs the operating path required by today's price achievable?
LiquidityMetCan the intended position be built and exited in the right vehicle?
DownsideMetThe Zydus Paragraph IV challenge to INGREZZA SPRINKLE breaks the settled 1 March 2038 generic wall years early on a franchise that is 80.5% of TTM revenue ($2,717.5m of $3,373.9m; $716.5m of $959.0m in Q2 2026 = 74.7%).
MomentumMetDoes price action support or complicate entry timing?
CatalystNot determinedTime works for a long; the calendar is dense and now materially SHARPER than the prior run: the Zydus binary has a derived date (~Sep 2027) where the prior record had none.
ConsensusNot determinedIs the house-versus-Street disagreement identified and quantified? Not established on the evidence on file.

Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.

Bottom line

The strongest case for mispricing is that the business already delivers +30.9 percentage points more growth than the price requires. The most important unresolved uncertainty is the permanent-loss mechanism: the Zydus Paragraph IV challenge to INGREZZA SPRINKLE breaks the settled 1 March 2038 generic wall years early on a franchise that is 80.5% of TTM revenue ($2,717.5m of $3,373.9m; $716.5m of $959.0m in Q2 2026 = 74.7%). The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $137.71, which forces an immediate review.